Minoryx receives Spanish clearance to begin phase II trial of MIN-102 in Friedreich's ataxia March 1, 2019
Apellis enters collaboration with SFJ Pharmaceuticals for APL-2 in hematologic indications March 1, 2019
Single-nulceotide polymorphism in ADGRL3 gene found predictor of substance use disorder March 1, 2019
Takeda Pharmaceutical presents the discovery of novel potent and selective Nav1.1 activator March 1, 2019
Bromodomain-containing protein 4 inhibitors identified at Zhejiang Hisun Pharmaceutical March 1, 2019
RSS